Alpha-1-antitrypsin and other proteinase inhibitors

Current Opinion in Pharmacology

Volumn 12, Issue 3, 2012, Pages 309-314

  Miravitlles, Marc ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

3 INDOLEMETHANOL; ALPHA 1 ANTITRYPSIN; AZD 9668; BETA LACTAM; FRESELESTAT; PEPTIDE ALDEHYDE; PEPTIDE BORONIC ACID; PEPTIDE CHLOROMETHYL KETONE; PLACEBO; PROTEINASE INHIBITOR; SIVELESTAT; TIOTROPIUM BROMIDE; TRIPEPTIDE KETONE; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADVERSE OUTCOME; ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DYSPNEA; HEADACHE; HUMAN; LUNG EMPHYSEMA; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STEADY STATE;

EID: 84862298546     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.02.004     Document Type: Review

References (40)

1. M. Miravitlles, J.B. Soriano, F. García-Río, L. Muñoz, E. Duran-Taulería, G. Sánchez, V. Sobradillo, and J. Ancochea Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities Thorax 64 2009 863 868
2. American Thoracic Society/European Respiratory Society Statement Standards for the diagnosis and management of individuals with alpha1-antitrypsin deficiency Am J Respir Crit Care Med 168 2003 818 900
3. L.T. Spencer, G. Paone, P.M. Krein, F.N. Rouhani, J. Rivera-Nieves, and M.L. Brantly Role of human neutrophil peptides in lung inflammation associated with alpha1-antitrypsin deficiency Am J Physiol Lung Cell Mol Physiol 286 2004 L514 L520
4. D.A. Lomas, and H. Parfrey Alpha1-antitrypsin deficiency. 4: Molecular pathophysiology Thorax 59 2004 529 535
5. J.K. Stoller, and L.S. Aboussouan Alpha1-antitrypsin deficiency Lancet 365 2005 2225 2236
6. V. Quesada, G.R. Ordóñez, L.M. Sánchez, X.S. Puente, and C. López-Otín The degradome database: mammalian proteases and diseases of proteolysis Nucleic Acids Res 37 Suppl. 1 2009 D239 D243
7. C. López-Otín, and J.S. Bond Proteases and multifunctional enzymes in life and disease J Biol Chem 283 2008 30433 30437
8. G. Tirado-Conde, B. Lara, and M. Miravitlles Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency Ther Adv Respir Dis 2 2008 13 21
9. A. Janoff Inhibition of human granulocyte elastase by serum alpha-1-antitrypsin Am Rev Respir Dis 105 1972 121 122
10. R. Vidal, I. Blanco, F. Casas, R. Jardí, M. Miravitlles, and National Alpha-1-antitrypsin Registry Committee Guidelines for the diagnosis and management of alpha-1-antitrypsin deficiency Arch Bronconeumol 42 2006 645 659
11. M.D. Wewers, M.A. Casolaro, S.E. Sellers, S.C. Swayze, K.M. McPhaul, J.T. Wittes, and R.G. Crystal Replacement therapy for alpha-1-antitrypsin deficiency associated with emphysema N Engl J Med 316 1987 1055 1062
12. A.R. Tonello, and M.L. Brantly Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies Ther Adv Respir Dis 4 2010 289 312
13. J.K. Stoller, R. Fallat, M.D. Schluchter, R.G. O'Brien, J.T. Connor, N. Gross, K. O'Neil, R. Sandhaus, and R.G. Crystal Augmentation therapy with alpha-1-antitrypsin: patterns of use and adverse events Chest 123 2003 1425 1434
14. D. Soy, C. de la Roza, B. Lara, C. Esquinas, A. Torres, and M. Miravitlles Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics Thorax 61 2006 1059 1064
15. G. Tirado-Conde, B. Lara, F. Casas, I. Blanco, A. Bustamante, S. Cadenas, M.T. Martínez, L. Lázaro, M. Torres, and J.M. Hernández Pérez Factors associated with the evolution of lung function in patients with alpha-1-antitrypsin deficiency in the Spanish Registry Arch Bronconeumol 47 2011 495 503
16. A. Dirksen, J.H. Dijkman, F. Madsen, B. Stoel, D.C. Hutchison, C.S. Ulrik, L.T. Skovgaard, A. Kok-Jensen, A. Rudolphs, and N. Seersholm A randomized clinical trial of alpha-1-antitrypsin augmentation therapy Am J Respir Crit Care Med 160 1999 1468 1472
17. A. Dirksen, E. Piitulainen, D.G. Parr, C. Deng, M. Wencker, S.B. Shaker, and R.A. Stockley Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1-antitrypsin deficiency Eur Respir J 33 2009 1345 1353
18. R.A. Stockley, D.G. Parr, E. Piitulainen, J. Stolk, B.C. Stoel, and A. Dirksen Therapeutic efficacy of alpha-1 antitrypsin augmentation therapy on the loss of lung tissue: an integrated analysis of 2 randomised clinical trials using computed tomography densitometry Respir Res 11 2012 136
19. R.A. Sandhaus, G. Turino, J. Stocks, C. Strange, B.C. Trapnell, E.K. Silverman, S.E. Everett, and J.K. Stoller Alpha-1-antitrypsin augmentation therapy for PI*MZ heterozygotes. A cautionary note Chest 134 2008 831 834
20. T. Kuraki, M. Ishibashi, M. Takayama, M. Shiraishi, and M. Yoshida A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats Am J Respir Crit Care Med 166 2002 496 500
21. S.D. Lucas, E. Costa, R.C. Guedes, and R. Moreira Targeting COPD: advances on low-molecular-weight inhibitors of human neutrophil elastase Med Res Rev 2011 10.1002/med.20247
22. C. Vogelmeier, T.O. Aquino, C.D. O'Brien, J. Perrett, and K.A. Gunawardena A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase in patients with chronic obstructive pulmonary disease treated with tiotropium COPD 2012 10.3109/15412555.2012.641803 posted online 17 Jan 2012
23. H.H. Nguyen, I. Aronchik, G.A. Brar, D.H.H. Nguyen, L.F. Bjeldanes, and G.L. Firestone The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing PNAS 105 2008 19750 19755
24. P.J. Barnes Emerging pharmacotherapies for COPD Chest 134 2008 1278 1286
25. A. Churg, A. Wang, X. Wang, P.O. Onnervik, K. Thim, and J.L. Wright Effect of an MMP-9/MMp-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs Thorax 62 2007 706 713
26. M. Schwaiblmair, C. Vogelmeier, and G. Fruhmann Long-term augmentation therapy in twenty patients with severe alpha-1-antitrypsin deficiency - three-year follow-up Respiration 64 1997 10 15
27. E.W. Schmidt, B. Rasche, W.T. Ulmer, N. Konietzko, M. Becker, J.P. Fallise, J. Lorenz, and R. Ferlinz Replacement therapy for alpha-1-protease inhibitor deficiency in PiZ subjects with chronic obstructive lung disease Am J Med 84 Suppl. 6A 1988 63 99
28. M. Wencker, N. Banik, R. Buhl, R. Seidel, and N. Konietzko Long-term treatment of alpha1 antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group Eur Respir J 11 1998 428 433
29. A.F. Barker, F. Siemsen, D. Pasley, R. D'Silva, and A.S. Buist Replacement therapy for hereditary alpha-1-antitrypsin deficiency. A program for long-term administration Chest 105 1994 1406 1410
30. M. Miravitlles, R. Vidal, M. Torrella, J.M. Bofill, M. Cotrina, and J. de Gracia Assessment of alpha-1-antitrypsin replacement therapy for emphysema Arch Bronconeumol 30 1994 479 484
31. R.C. Hubbard, S. Sellers, D. Czerski, L. Stephens, and R.G. Crystal Biochemical efficacy and safety of monthly augmentation therapy for alpha-1-antitrypsin deficiency JAMA 260 1988 1259 1264
32. N. Padullés Zamora, R. Vidal Pla, P. Gispert del Río, R. Jardí Margalef, F. Rodríguez Frías, and J.B. Montoro Rosano Intravenous human plasma-derived augmentation therapy in alpha-1-antitrypsin deficiency: from pharmacokinetic analysis to individualising therapy Ann Pharmacother 42 2008 640 646
33. E. Piitulainen, E. Bernspang, S. Björkman, and E. Berntorp Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha-1 antitrypsin Eur J Clin Pharmacol 59 2003 151 156
34. N. Seersholm, M. Wencker, N. Banik, K. Viskum, A. Dirksen, A. Kok-Jensen, and N. Konietzko Does alpha-1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha-1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group Eur Respir J 10 1997 2260 2263
35. Alpha-1-antitrypsin deficiency Registry Study Group: Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin: The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998, 158:49-59.
36. D.J. Gottlieb, M. Luisetti, P.J. Stone, L. Allegra, J.M. Cantey-Kiser, C. Grassi, and G.L. Snider Short-term supplementation therapy does not affect elastin degradation in severe alpha-1-antitrypsin deficiency. The American-Italian AATD Study Group Am J Respir Crit Care Med 162 2000 2069 2072
37. J. Lieberman Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data Chest 118 2000 1480 1485
38. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen Longitudinal follow-up of patients with alpha-1-protease inhibitor deficiency before and during therapy with alpha-1-protease inhibitor Chest 119 2001 737 744
39. R.A. Stockley, D.L. Bayley, I. Unsal, and L.J. Dowson The effect of augmentation therapy on bronchial inflammation in alpha1-antitrypsin deficiency Am J Respir Crit Care Med 165 2002 1494 1498
40. J.K. Stoller, and L.S. Aboussonan Alpha-1-antitrypsin deficiency. 5: Intravenous augmentation therapy: current understanding Thorax 59 2004 708 712